With a projected market for regenerative medicine of $500 billion by 2020 in the U.S. alone, states are right to fund economic programs targeting stem cell research and biotechnology, but politicians can’t be short-sighted by demanding short-term payoffs.

0

Submit a comment

Your email address will not be published. Required fields are marked *

There are 0 comments